The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma

Nisreen AA Osman*, Alzahraa Ibrahim Khalil, Rehab Kamal Yousef

Abstract

Objectives: This study aimed to investigate the expression of SOX2, SOX9, p53, and β-catenin in hepatocellular carcinoma (HCC) and their correlation with clinicopathological parameters of prognostic importance. Materials and Methods: Seventy-five patients were enrolled in this study. All patients had full clinical and follow-up data and available paraffin blocks. Immunohistochemical analysis was performed and correlated with clinicopathological factors and patient survival. Results: We detected the positive expression of SOX2, SOX9, p53, and β-catenin in 76%, 50.7%, 50.7%, and 77.9% of HCC specimens respectively. All studied markers showed a significant increase in the expression in tumor tissue specimens compared to non-tumor tissue. Both SOX2 and SOX9 expressions were significantly associated with adverse prognostic factors in HCC. Significant positive correlations were found between SOX2 and SOX9 and both p53 and β-catenin expression (r= 0.528, 0.485 and; r = 0.253, 0.327, respectively; p< 0.0001 for both of them). Regarding survival, we found that HCC patients with positive SOX2 and SOX9 expressions had significantly shorter overall survival (p=0.0001, each). Additionally, larger tumor size, tumor grade, high stage, tumor multiplicity, presence of cirrhosis, tumor necrosis, high p53 expression, and positive β-catenin expression were independent predictors of worse survival. A multivariate Cox analysis revealed that tumor grade, stage, p53, and SOX2 expression were independent predictors of unfavorable prognosis in overall survival (p=0.0001, p=0.0001,p=0.033; and p=0.003, respectively). Conclusions: Our findings might provide an insight into SOX2 and SOX9’s role in HCC and suggest that SOX2 might be targeted for HCC therapy.

Keywords: HCC- SOX2- SOX9- p53- β-catenin

Introduction

Hepatocellular carcinoma (HCC) ranks the fifth most common cancer in men, the seventh most common cancer in women, and the third leading cause of cancer-related mortality in the world (Ozakyol, 2017; Petruzziello, 2018) It is the most common primary hepatic malignancy, constituting around 90% of primary liver cancers (Elghazaly et al., 2018).

In Egypt, HCC is a significant health burden. The incidence of HCC among all cancer types in Egypt is higher in males (33.63%) than in females (13.54%). The risk factors for HCC included hepatitis C and B infection, cirrhosis, metabolic syndromes, and alcohol abuse. Hepatitis C virus (HCV) is an epidemic that affected about 10-15% of people in Egypt (Elghazaly et al., 2018). Hepatocellular carcinoma related to chronic hepatitis C constitutes about 63% of cases and about 90% of them were of genotype 4 HCV infection (Yapali and Tozun, 2018). This leads to late discovery of HCC with subsequent poor prognosis (Elghazaly et al., 2018).

Multiple signaling pathways responsible for cellular proliferation, apoptosis, metabolism and cell cycle are established in HCC development. Several mutations in HCC are activated. They include mutations in the tumor suppressor gene p53, in CTNNB1Wnt/β-catenin pathway and others (Lee et al., 2014; Vilchez et al., 2016). Cancers exhibiting p53 mutations are reported to be more aggressive with resistance to chemotherapy (Mohamed et al., 2008; Aravalli et al., 2013).

β-catenin gene (CTNNB1), an oncogene encodes a β-catenin protein that plays a role in intercellular adhesion
Nisreen AA Osman et al

and involved in the development of HCC (Li et al., 2014; Wang et al., 2015). Notably, nucleocytoplasmic expression of β-catenin reflects a transcription factor function in the canonical Wnt/β-catenin signaling pathway, whereas membranous expression reveals its other function in cell-cell adhesion (Brembeck et al., 2006). Dysregulation of Wnt/β-catenin signaling is involved in early carcinogenesis and the aggressiveness of HCC. This implicates its role in cell survival, proliferation, and migration and invasion (Pez et al., 2013).

Despite the discovery of several pathways involved in hepatocarcinogenesis, still few of them are beneficial as targets for therapy and long term survival is still low. Therefore, there is a great demand for finding new targets involved in HCC progression. Sox (sex determining region Y) box gene superfamily, is incorporated in cell development, cell differentiation and embryonic stem cell properties. Also, it is considered as a transcriptional regulator (Lefebvre et al., 2007). Comparable to embryonic stem cells in organ development, cancer stem cells (CSCs) have the ability to initiate tumor development and resistance to both chemotherapy and radiotherapy (Dean et al., 2005; Phillips et al., 2006; O’Brien et al., 2007). So, the identification of CSC markers and their roles in cell signaling pathways might result in the construction of new therapeutic strategies.

The transcription factor SRY (sex-determining region Y)-box 2 plays a key role in maintaining the stemness properties in cancer cells as it is involved in the reprogramming of differentiated cells into induced pluripotent stem cells (Yu et al., 2007; Yuan et al., 2010). SOX2 was associated with tumor progression of many tumors such as gastric (Li et al., 2004), pancreatic (Sanada et al., 2006), breast (Rodriguez-Pinilla et al., 2007), colorectal cancers (Han et al., 2012), and osteosarcomas (Basu-Roy et al., 2012). In HCC, SOX2 is involved in the progression of HCC and correlated with an aggressive phenotype (Huang et al., 2011). However little is known about the molecular role of SOX2 in HCC.

The transcription factor-sex determining region Y-box 9-(Sox9), another member of Sox superfamily, plays a role in the organogenesis of several tissues. In hepatogenesis, Sox9 is expressed in the precursor cells during embryogenesis and during hepatocyte regeneration following liver injury (Furuyama et al., 2011; Yimlamai et al., 2014). Sox9 transcript level in HCC tissues is positively correlated with tumor grade, stage and poorer survival in HCC (Guo et al., 2012).

The Wnt signal pathway and P53 have been proven as cancer stem cells markers and Wnt signal pathway and P53 with clinicopathological features in cancers are still not elucidated.

In the present study, we aimed to investigate the expression of SOX2, SOX9 in HCC, and study their correlations with P53 and β-catenin. Also, to study their associations with clinicopathologic data and patient survival.

Materials and Methods

Tissue samples

This study consisted of 75 formalin-fixed, paraffin-embedded tissue specimens of hepatocellular carcinoma cases. They were chosen from the archives of the Pathology Department Minia, university Hospital during the period between 2009-2014. Forty-nine (49) cases were obtained by tru–cut biopsy and 26 cases were obtained by lobectomy. The pathology reports and hematoxylin and eosin (H&E) stained slides for all cases were reviewed to confirm the diagnosis. The histologic grade of HCC was done according to the 3-scale system; grade I, II and III (Schlageter et al., 2014). Tumors were staged according to the seventh edition of the tumor-node-metastasis (TNM) classification developed by the American Joint Committee on Cancer (AJCC) and International Union for Cancer Control (UICC) (Shindoh and Vauthey, 2014). Survival data was available for 3 years duration of patients’ follow up. The institutional ethics committees approving this research comply with the Declaration of Helsinki, 1975.

Immunohistochemistry

Four-micrometer tissue sections on positively charged slides were deparaffinized and rehydrated through xylene and graded ethanol solutions and then treated for 30 min with 3% hydrogen peroxide to block the endogenous peroxidase activity. For antigen retrieval, sections were treated with 0.1 mol/L citrate, pH 6.0, in a 700-W microwave oven for 20 min; ultra v block was added for slides of p53 immunostaining only for 5 minutes to block non-specific background staining. The sections were incubated overnight at 4°C in a humidity chamber with primary antibodies. Primary antibodies used were for p53 (monoclonal mouse antibody clone DO-7+BP53-12, ready to use, Lab Vision Laboratories), for β-catenin (polyclonal rabbit antibody, ready to use, Lab Vision Laboratories), for SOX2 (Novus BiologicalsUSA, at dilution of 1:100 in PBS) and for SOX9 (rabbit polyclonal antibody, Santa Cruz Biotechnology, Inc. USA, at dilution of 1:50).

The reaction was detected with the avidin-biotin detection kit using diaminobenzidine (DAB) as the chromogen. Sections were counterstained with Mayer’s hematoxylin for 15 seconds then distilled water, after that dehydrated through graded ethanol alcohol, cleared in xylene and coverslipped before checked under the microscope. Negative control tissue sections were processed by omitting the primary antibody and slides incubated with PBS. Positive control was processed for each antibody (colonic carcinoma for p53, breast carcinoma for β-catenin, lung squamous cell carcinoma...
Pluripotent Stem Cell Markers Expression and WNT Signal Pathway in Hepatocellular Carcinoma

Immunohistochemical Results
Expression of studied markers in non-tumor tissue specimens

Non-tumor tissue was found in 26 lobectomy cases and in 5 cases from tru-cut biopsies. Non-tumor tissue included areas of hepatitis or cirrhosis. High p53 expression was detected in hepatocytes adjacent to tumor tissue in 5/31 cases (16.1%). Positive β-catenin expression was found in the cytoplasm and nuclei of hepatocyte neighboring tumor areas in 8/31 cases (25.8%). Both SOX2 and SOX9 positive staining was detected in 21 cases (28%). The details about clinicopathological data were presented in Table 1.

Immunohistochemical scoring

Regarding p53, immunohistochemical expression was scored according to the percentage of nuclear positive tumor cells; the cutoff point was chosen as the median value of the average staining percentage which was 7%. Cases with a nuclear expression more than 7% are considered higher expression while cases with expression lower than 7% considered lower expression. For β-catenin, positive tumor cells were defined as cells with membranous and/or cytoplasmic staining. The median value of the average staining percentage was used as a cutoff point and it was 30% for both staining patterns. SOX2 immunostaining was scored according to the percentage of nuclear positive tumor cells; negative (if the percentage of stained tumor cells is ≤10) or positive (if percentage is>10 %) (Sun et al., 2013; Aboushousha et al., 2018). The cut-off value of positivity for SOX9 staining was set to 5% positive tumor cells/per 10 HPF (Richtig et al., 2017).

Statistical analysis

Chi-square and Fisher’s exact tests were used to compare categorical variables. Correlation between markers was evaluated using Spearman’s correlation coefficient. Results were considered statistically significant when the P value < 0.05. Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 17 software.

Survival analysis

Kaplan-Meier survival curves and log-rank test statistics were employed to calculate three year overall patients’ survival and their differences. Multivariate regression analysis was carried out using Cox regression to assess the specific influence of each variable on survival in the presence of other variables. Only variables of significant value from the univariate analysis were entered into the Cox regression analysis. Hazard ratios (HRs) estimated from Cox models were reported as relative risks with corresponding 95% confidence intervals (CIs). A P value of <0.05 was considered significant.

Results

Clinicopathological parameters:

The current study included 75 paraffin blocks from cases for patients suffering from hepatocellular carcinoma. The mean patients’ + age SD was 63.95 + 10.629 years and the median age was 63 years (ranged from 26-87 years). Most cases of male patients were in the age group less than the mean; 37 (62.7%) cases, while the majority of females were aged higher than the mean age; 12 (75%) and this difference was statistically significant (p<0.007). Hepatitis virus infection was found in 49 cases (65.3%). Hepatitis C virus infection was detected in 33 cases (67.7%) and hepatitis B virus infection was detected in 16 cases (32.7%). Collectively, there were more HCCs in male patients (59 cases, 78.7%); in cirrhotic livers (50 cases, 66.7%); with tumor grade 2 (38 cases, 50.7%) and with tumor stage III (27 cases, 36%). Fatty change was observed in non-tumor tissue in 8 cases (10.7%). Tumor tissue necrosis was found in 21 cases (28%). The details about clinicopathological data were presented in Table 1.

Table 1. Clinicopathological Features of Patients with HCC (n= 75)

| Clinicopathological features | Number (Percentage %) |
|-----------------------------|-----------------------|
| Age (years)                 |                       |
| <64                         | 41 (54.7)             |
| >64                         | 34 (45.3)             |
| Sex                         |                       |
| Male                        | 59 (78.7)             |
| Female                      | 16 (21.3)             |
| Hepatitis                   |                       |
| Negative                    | 26 (34.7)             |
| Positive                    | 49 (65.3)             |
| Fatty change                |                       |
| Absent                      | 67 (89.3)             |
| Present                     | 8 (10.7)              |
| Cirrhosis                   |                       |
| No                          | 25 (33.3)             |
| Yes                         | 50 (66.7)             |
| Tumor size (cm)             |                       |
| <5 cm                       | 30 (40)               |
| >5 cm                       | 45 (60)               |
| Tumor Focality              |                       |
| Solitary                    | 36 (48)               |
| Multifocal                  | 39 (52)               |
| Tumor necrosis              |                       |
| Absent                      | 54 (72)               |
| Present                     | 21 (28)               |
| Tumor Grade                 |                       |
| I                           | 20 (26.7)             |
| II                          | 38 (50.7)             |
| III                         | 17 (22.6)             |
| Tumor Stage                 |                       |
| I                           | 19 (25.3)             |
| II                          | 17 (22.7)             |
| III                         | 27 (36)               |
| IV                          | 12 (16)               |
High p53 expression was found in 38/75 (50.7%) of HCC cases (Figure 1a). High p53 expression was significantly more with the absence of fatty change and necrosis (p <0.028, <0.002 respectively). A statistically significant positive association was detected between high p53 expression and adverse prognostic factors of HCC including; larger tumor size, higher tumor grade and stage (p <0.048, =0.001, <0.006 respectively). Otherwise, no significant associations were found as seen in Table 3.

Table 2. Comparison between Expression of Studied Markers in Tumor Tissue (Number 75) and Adjacent Non Tumor Tissue (number 31)

| Marker | Non tumor tissue number (%) | Tumor tissue number (%) | P value |
|--------|-----------------------------|-------------------------|---------|
| P53    |                             |                         |         |
| low    | 26 (83.9)                   | 37 (49.3)               | 0.001*  |
| high   | 5 (16.1)                    | 38 (50.7)               |         |
| β catenin |                         |                         |         |
| Negative | 23 (74.2)               | 19 (25.3)               | 0.0001* |
| Positive | 8 (25.8)                  | 56 (74.7)               |         |
| SOX2   |                             |                         |         |
| Negative | 24 (77.4)                 | 18 (24)                 | 0.001*  |
| Positive | 7 (22.6)                   | 57 (76)                 |         |
| SOX9   |                             |                         |         |
| Negative | 27 (87.1)                 | 30 (40)                 | 0.0001* |
| Positive | 4 (12.9)                   | 38 (50.7)               |         |

Test of significance: Chi-square X² and Fisher's exact tests. P-value < 0.05 is considered significant*.
β-catenin expression

The incidence of abnormal β-catenin (decreased membranous and/or increased cytoplasmic and nuclear expressions) was variable in HCC studied cases (Figure 1b). Combined cytoplasmic and membranous localization was found in 26 cases (30.2%); variable cytoplasmic or membranous localization was found in 30 cases (34.9%, Fig.1c); while 19 cases (22.1%) lacked any β-catenin staining. Nuclear expression of β-catenin was observed in 6 cases; combined with cytoplasmic and membranous expression, 4 of them were grade III and 2 of them were grade II (Fig.1d). As, the nuclear stain was detected in a low number of cases, they were not included in statistical analysis. A statistically significant positive association was detected between abnormal β-catenin expression and hepatitis infection, tumor size and tumor grade and stage (p <0.009, <0.008, <0.005 respectively) as shown in Table 4.

SOX2 and SOX9 Expression

SOX2 positive expression was located mainly in the

---

**Table 3. Associations between Immunohistochemical Expression of p53 and Clinicopathological Parameters in Hepatocellular Carcinomas Cases (75 Cases)**

| Parameter               | P53 expression | P-value |
|-------------------------|----------------|---------|
|                         | -ve/low expression (%) | High expression (%) |         |
| Age (years)             |                |         |
| <64                     | 18 (48.6)      | 23 (60.5) | 0.302   |
| >64                     | 19 (51.4)      | 15 (39.5) |         |
| Sex                     |                |         |
| Male                    | 31 (83.8)      | 28 (73.7) | 0.286   |
| Female                  | 6 (16.2)       | 10 (26.3) |         |
| Hepatitis               |                |         |
| Negative                | 10 (27)        | 16 (42.1) | 0.17    |
| Positive                | 27 (73)        | 22 (57.1) |         |
| Fatty change            |                |         |
| Absent                  | 30 (81.1)      | 37 (97.4) | 0.028*  |
| Present                 | 7 (18.9)       | 1 (2.6)   |         |
| Cirrhosis               |                |         |
| No                      | 16 (43.2)      | 9 (23.7)  | 0.072   |
| Yes                     | 21 (56.8)      | 29 (76.3) |         |
| Tumor size (cm)         |                |         |
| <5 cm                   | 19 (51.4)      | 11 (28.9) | 0.048*  |
| >5 cm                   | 18 (48.6)      | 27 (71.1) |         |
| Tumor Focality          |                |         |
| Solitary                | 21 (56.8)      | 15 (39.5) | 0.134   |
| Multifocal              | 16 (43.2)      | 23 (60.5) |         |
| Tumor necrosis          |                |         |
| Absent                  | 33 (89.2)      | 21 (55.3) | 0.002*  |
| Present                 | 4 (10.8)       | 17 (44.7) |         |
| Tumor Grade             |                |         |
| I                       | 18 (48.6)      | 2 (5.3)   | 0.0001* |
| II                      | 16 (43.2)      | 22 (57.9) |         |
| III                     | 3 (8.1)        | 14 (36.8) |         |
| Tumor Stage             |                |         |
| I                       | 16 (43.2)      | 3 (7.9)   | 0.006*  |
| II                      | 6 (16.2)       | 11 (28.9) |         |
| III                     | 11 (29.7)      | 16 (42.1) |         |
| IV                      | 4 (10.8)       | 8 (21.1)  |         |

Test of significance: Chi-square X^2 and Fisher's exact tests; P-value < 0.05 is considered significant*

**Table 4. Associations between Immunohistochemical Combined Expression of β-catenin and Clinicopathological Parameters in Hepatocellular Carcinomas Cases (75 Cases)**

| Parameter               | Combined β-catenin expression | P-value |
|                        | -ve/-ve (%) | -ve/+ve or +ve/-ve (%) | +ve/+ve (%) |         |
| Age (years)             |                |         |
| <64                     | 12 (63.2)      | 16 (53.3) | 13 (50) | 0.669  |
| >64                     | 7 (36.8)       | 14 (46.7) | 13 (50) |         |
| Sex                     |                |         |
| Male                    | 12 (63.2)      | 25 (83.3) | 22 (84.6) | 0.16   |
| Female                  | 7 (36.8)       | 5 (16.7)  | 4 (15.4) |         |
| Hepatitis               |                |         |
| Negative                | 5 (26.3)       | 6 (20)    | 15 (57.1) | 0.009* |
| Positive                | 14 (73.7)      | 24 (80)   | 11 (42.3) |         |
| Fatty change            |                |         |
| Absent                  | 17 (89.5)      | 28 (93.3) | 22 (84.6) | 0.574  |
| Present                 | 2 (10.5)       | 2 (6.7)   | 4 (15.4) |         |
| Cirrhosis               |                |         |
| No                      | 8 (42.1)       | 8 (26.7)  | 9 (34.6)  | 0.528  |
| Yes                     | 11 (57.9)      | 22 (73.3) | 17 (65.4) |         |
| Tumor size (cm)         |                |         |
| <5 cm                   | 13 (68.4)      | 11 (36.7) | 6 (23.1)  | 0.008* |
| >5 cm                   | 6 (31.6)       | 19 (63.3) | 20 (76.9) |         |
| Tumor Focality          |                |         |
| Solitary                | 12 (63.2)      | 15 (50)   | 6 (31.6)  | 0.294  |
| Multifocal              | 7 (36.8)       | 15 (50)   | 13 (68.4) |         |
| Tumor necrosis          |                |         |
| Absent                  | 17 (89.5)      | 19 (63.3) | 18 (69.2) | 0.129  |
| Present                 | 2 (10.5)       | 11 (36.7) | 8 (30.8)  |         |
| Tumor Grade             |                |         |
| I                       | 10 (52.6)      | 8 (26.7)  | 2 (7.7)   | 0.005* |
| II                      | 6 (31.6)       | 18 (60)   | 14 (53.8) |         |
| III                     | 3 (15.8)       | 4 (13.3)  | 10 (38.5) |         |
| Tumor Stage             |                |         |
| I                       | 8 (42.1)       | 9 (30)    | 2 (7.7)   | 0.074  |
| II                      | 5 (26.3)       | 5 (16.7)  | 7 (26.9)  |         |
| III                     | 3 (15.8)       | 10 (33.3) | 14 (53.8) |         |
| IV                      | 3 (15.8)       | 6 (20)    | 3 (11.5)  |         |

Test of significance: Chi-square X^2 and Fisher's exact tests. P-value < 0.05 is considered significant*. -ve/-ve: negative cytoplasmic and negative membranous expression; -ve/+ve or +ve/-ve: negative cytoplasmic, positive membranous expression or positive cytoplasmic, negative membranous expression; +ve/+ve : positive cytoplasmic and positive membranous expression.
nucleus with scanty cytoplasmic staining (Figure 2a, b). We found 57 of 75 (76%) HCC cases positive for that SOX2 expression. SOX2 positivity was significantly associated with younger age (p<0.037), male gender (p< 0.006) and presence of cirrhosis (p<0.0001). Regarding tumor characteristics, SOX2 positivity was significantly associated with larger tumor size (p<0.0001), with multiple tumors (p<0.0001), with the decreased amount of necrosis (p<0.02) and increasing tumor grade and stage of HCC (p<0.0001 for both) (detailed in Table 5).

Positive SOX9 expression was located mainly in the nuclei of neoplastic cells with accompanied cytoplasmic expression in 40 cases (Figure 2c, d). We found 38 of 75 (50.7%) HCC cases positive for that SOX9 expression. Negative SOX9 expression was observed in 10/75 (13.3%) cases and low SOX9 expression was found in 27/75 (36%) of HCC cases. SOX9 positivity was significantly associated with male gender (p< 0.021) and presence of cirrhosis (p<0.022). Regarding tumor characteristics, SOX2 positivity was significantly associated with larger tumor size (p<0.0001), with multiple tumors (p<0.0001), with the decreased amount of necrosis (p<0.025) and increasing tumor grade and stage of HCC (p<0.0001 for both) (detailed in Table 5).

**Relationship between expressions of studied markers in HCC cases**

The present work found that SOX2 and SOX9 expression rates were positively correlated with each other’s (Spearman’s rho correlation; rs= 0.766; p< 0.0001). A significant positive correlation was found between SOX2 and both p53 and β-catenin expression (Spearman’s rho correlation; rs= 0.528, 0.485 respectively; p< 0.0001 for both of them). Similarly, a significant positive correlation was found between SOX9 and both p53 and β-catenin expression (Spearman’s rho correlation; rs= 0.253, 0.327 respectively; p< 0.028, 0.004 respectively). A significant correlation was found between p53 and β-catenin expression rates (Spearman’s rho correlation; rs= 0.381; p< 0.0001). In HCC cases 38/75 (50.7%) were positive for both SOX2 and SOX9 expression (p= 0.001), 25/75 (33.3%) were negative for both of them and variable expression in 12/75 (16%) cases.

**Correlation between expressions of studied markers and survival of patients**

The median overall survival period was 28 months (range 12-36 months) and the mean follow up period was 27.2 months. Forty patients (53.3 % of all cases studied) died during 3 years follow up. Using Kaplan- Meier method and log-rank test, there were significant associations between shorter overall survival of HCC and larger tumor size (p =0.0001), tumor grade (p =0.0001), high stage (p =0.0001), tumor multiplicity (p =0.0001), presence of cirrhosis (p =0.020), tumor necrosis (p =0.027), high p53 expression (p=0.0001), positive β-catenin expression (p=0.009), positive SOX2 expression (p=0.0001) and positive SOX9 expression (p=0.0001). On the other hand, no significant association was found between overall
Table 5. Associations between Immunohistochemical Expression of SOX2, SOX9 and Clinicopathological Parameters in Hepatocellular Carcinomas Cases (75 Cases)

| Parameter               | SOX2 expression | P value | SOX9 expression | P value |
|-------------------------|-----------------|---------|-----------------|---------|
|                         | Negative (%)    | Positive (%) |                | Negative (%) | Positive (%) |
| Age (years)             |                 |         |                 |          |
| <64                     | 6 (33.3)        | 35 (61.4) | 0.037*          | 20 (54.1) | 21 (55.3) | 0.916 |
| >64                     | 12 (66.7)       | 22 (38.6) |                 | 17 (45.9) | 17 (44.7) |
| Sex                     |                 |         |                 |          |
| Male                    | 10 (55.6)       | 49 (86)  | 0.006*          | 25 (67.6) | 34 (89.5) | 0.021* |
| Female                  | 8 (44.4)        | 8 (14)   |                 | 12 (32.4) | 4 (10.5)  |
| Hepatitis               |                 |         |                 |          |
| Negative                | 4 (22.2)        | 22 (38.6) | 0.262           | 15 (40.5) | 11 (28.9) | 0.292 |
| Positive                | 14 (77.8)       | 35 (61.4) |                 | 22 (59.5) | 27 (71.1) |
| Fatty change            |                 |         |                 |          |
| Absent                  | 14 (77.8)       | 53 (93)  | 0.088           | 33 (89.2) | 34 (89.5) | 0.968 |
| Present                 | 4 (22.2)        | 4 (7)    |                 | 4 (10.8)  | 4 (10.5)  |
| Cirrhosis               |                 |         |                 |          |
| No                      | 14 (77.8)       | 11 (19.3) | 0.0001*         | 17 (45.9) | 8 (21.1)  | 0.022* |
| Yes                     | 4 (22.2)        | 46 (80.7) |                 | 20 (54.1) | 30 (78.9) |
| Tumor size (cm)         |                 |         |                 |          |
| <5 cm                   | 18 (100)        | 12 (21.1) | 0.0001*         | 28 (75.7) | 2 (5.3)   | 0.0001* |
| >5 cm                   | 0 (0)           | 45 (78.9) |                 | 9 (24.3)  | 36 (94.7) |
| Tumor Focality          |                 |         |                 |          |
| Solitary                | 18 (100)        | 18 (31.6) | 0.0001*         | 32 (86.5) | 4 (10.5)  | 0.0001* |
| Multifocal              | 0 (0)           | 39 (68.4) |                 | 5 (13.5)  | 34 (89.5) |
| Tumor necrosis          |                 |         |                 |          |
| Absent                  | 18 (100)        | 36 (63.2) | 0.002*          | 31 (83.8) | 23 (60.5) | 0.025* |
| Present                 | 0 (0)           | 21 (36.8) |                 | 6 (16.2)  | 15 (39.5) |
| Tumor Grade             |                 |         |                 |          |
| I                       | 18 (100)        | 2 (3.5)  | 0.0001*         | 20 (54.1) | 0 (0)     | 0.0001* |
| II                      | 0 (0)           | 38 (66.7) |                 | 14 (37.8) | 24 (63.2) |
| III                     | 0 (0)           | 17 (29.8) |                 | 3 (8.1)   | 14 (36.8) |
| Tumor Stage             |                 |         |                 |          |
| I                       | 18 (100)        | 1 (1.8)  | 0.0001*         | 19 (51.4) | 0 (0)     | 0.0001* |
| II                      | 0 (0)           | 17 (29.8) |                 | 14 (37.8) | 3 (7.9)   |
| III                     | 0 (0)           | 27 (47.4) |                 | 4 (10.8)  | 23 (60.5) |
| IV                      | 0 (0)           | 12 (21.1) |                 | 0 (0)     | 12 (31.6) |

Test of significance: Chi-square X2 and Fisher's exact tests; P-value < 0.05 is considered significant*.

In multivariate analysis, only tumor grade and stage among clinicopathological features have impact on overall survival (p=0.001 for each). Regarding studied markers; p53 and SOX2 expression were independent predictor factors for overall survival (p=0.033; 0.003 respectively as shown in Table 6).

Discussion

Hepatocellular carcinoma is one of the most lethal malignancies. Despite the improvement in diagnosis and treatment modalities, the prognosis of HCC is still worse mainly due to high recurrence rate of HCC after resection (Fernandez-Sevilla et al., 2017).

The aim of the present study was to investigate whether p53, β-catenin, SOX2 and SOX9 as a group of markers; act as transcription factors that are involved in hepatocarcinogenesis; could predict the malignant behavior of HCCs. In addition, we analyzed their prognostic value, their inter-correlation and their correlation to other histopathological parameters. Our positivity rates of the forementioned markers obtained by immunohistochemical assessment were in agreement with ranges reported in the literature (Guo et al., 2012; Sun et al., 2013; Liu et al., 2016; Richtig et al., 2017; Aboushousha et al., 2018; Khalaf et al., 2018).

Many studies had focused on the activation of...
Wnt/β-catenin pathway and reported the involvement of various regulatory mechanisms that led to better understanding for their role in hepatocarcinogenesis. Upon comparing the expression of the studied markers in tumor and non tumor tissue, it was found that tumor tissue had significantly higher rates of expression. The same finding was reported in previous studies (Lee et al., 2014; Zhao et al., 2015; Richtig et al., 2017; Aboushousha et al., 2018; Khalaf et al., 2018).

Many studies suggest that the presence of β-catenin mutation in HCC tumors is associated with prognosis and tumor behavior. Previous studies reported that the expression of β-catenin in the nucleus and cytoplasm may also be associated with high tumor grade, advanced stage and shorter overall survival (Lee et al., 2014; Lu et al., 2014; Zhao et al., 2015; Vilchez et al., 2016; Khalaf et al., 2018). The overexpression of p53 in this study is associated with larger tumor size, higher grade and stage and with shorter overall survival. Similar results were obtained in previous studies (Stroescu et al., 2008; Liu et al., 2016). The present study showed increased positivity of β-catenin and p53 expression in viral associated HCC than in non-viral HCC. The same result was reported previously (Liu et al., 2016; Khalaf et al., 2018).

It was reported that SOX2 plays a pivotal role in oncogenesis and progression of multiple cancers including HCC (Sun et al., 2013; Zhao et al., 2015). In line with our results, It was found that immunohistochemical expression of SOX2 was more frequently over-expressed in HCC tissue compared to non-tumor tissue (Sun et al., 2013; Aboushousha et al., 2018). This result was confirmed by western blot, cell culture and qPCR analyses (Sun et al., 2013; Yin et al., 2013; Zhong et al., 2017).

Our results showed that high expression of both SOX2 and SOX9 were significantly correlated with larger tumor size, tumor multiplicity, higher tumor grade, pathological stage and poor overall survival in univariate analysis. This was compatible with previous studies (Sun et al., 2013; Richtig et al., 2017; Aboushousha et al., 2018).

In this study, we found that both the high expression of SOX2 and SOX9 were significantly associated with increased β-catenin expression and p53 expression. To our knowledge, this is the first study to assess the association between SOX2 and SOX9 and the Wnt signal pathway in HCC. Considering other tissues, a significant association was identified between the expression of Sox2 and β-catenin in cervical squamous cell carcinoma and lung carcinoma (Ji et al., 2014; Samulin Erdem et al., 2016; Guo et al., 2018). Additionally, we found that both the high expression of SOX2 and SOX9 were significantly associated with increased p53 expression. To our knowledge, this is the first study to the association between SOX2 and SOX9 and p53 in HCC. Considering other tissues, similar finding in NSCLC, SOX2 and TP53 expression were correlated (Samulin Erdem et al., 2016).

With regard to survival, we found that HCC patients with high p53 expression, high β-catenin expression, high SOX9 expression and low SOX2 expression had significantly worse survival time than those with low p53, β-catenin, and SOX9 and SOX2 expression by Kaplan–Meier analysis. Our findings suggested that p53, β-catenin, SOX9 and SOX2 possibly considered as a prognostic biomarkers in HCC. The same finding was reported by previous studies (Sun et al., 2013; Leung et al., 2016; Richtig et al., 2017; Zhang et al., 2019).

On the level of multivariate analysis, only the high expression level of p53 and the low expression level SOX2 were associated with unfavorable prognosis in HCC. Taken together, p53 and SOX2 could be used as prognostic factors and be objected for molecular targeted therapy in HCC patients. An association between TP53 mutations and SOX2 copy number alterations was reported in lung cancer (Samulin Erdem et al., 2016). From the aforementioned results we can conclude that the upregulation of Sox2 may play an important oncogenic role in HCC and can be considered as an acquired malignant proliferative phenotypic feature of tumor cells.

More research is needed to determine the effect of molecular therapy targeting the stemness of Wnt/β-catenin pathway for treatment of HCC. Also, to investigate the possible regulation of P53 on SOX2 in several different HCC cell lines, as well as on molecular levels.

Acknowledgment

This study was approved by the institutional ethics
References

Aboushousha T, Mamdouh S, Hamdy H, et al (2018). Immuno-histochemical and Biochemical Expression Patterns of TTF-1, RAGE, LUT-1 and SOX2 in HCV-Associated Hepatocellular Carcinomas. Asian Pac J Cancer Prev, 19, 219-27.

Aravalli RN, Cressman EN, Steer CJ (2013). Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol, 87, 227-47.

Basu-Roy U, See O, Ramanathapuram L, et al (2012). Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene, 31, 2270-82.

Brembeck FH, Rosa rio M, Birchmeier W (2006). Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev, 16, 51-9.

Dean M, Fojo T, Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer, 5, 275-84.

Elghazaly H, Gaballah A, Bahie Eldin N (2018). Clinicopathological pattern of hepatocellular carcinoma (HCC) in Egypt. Ann Oncol, 29, 5.

Fernandez-Sevilla E, Allard MA, Selten J, et al (2017). Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?. Liver Transpl, 23, 440-7.

Furuyama K, Kawaguchi Y, Akiyama H, et al (2011). Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet, 43, 34-41.

Guo X, Xiong L, Sun T, et al (2012). Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol, 7, 44.

Guo YZ, Xie XL, Fu J, Xing GL (2018). SOX9 regulated proliferation and apoptosis of human lung cancer cells by the Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci, 22, 4896-4907.

Han X, Fang X, Lou X, et al (2012). Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS One, 7, e41335.

Huang P, Qiu J, Li B, et al (2011). Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem, 44, 582-9.

Ji J, Wei X, Wang Y (2014). Embryonic stem cell markers Sox-2 and OCT4 expression and their correlation with WNT signal pathway in cervical squamous cell carcinoma. Int J Clin Exp Pathol, 7, 2470-6.

Khalaﬁ AM, Fuentes D, Morshid AI, et al (2018). Role of Wnt/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical signiﬁcance. J Hepatocell Carcinoma, 5, 61-73.

Lee JM, Yang J, Newell P, et al (2014). Beta-catenin signaling in hepatocellular cancer: Implications in inﬂammation, ﬁbrosis, and proliferation. Cancer Lett, 343, 90-7.

Lefebvre V, Dumitruc B, Penzo-Mendez A, Han Y, Pallavi B (2007). Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol, 39, 2114-95.

Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer, 9, 749-58.

Leung CO MW, Kai AK, Chan K, et al (2016). Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/beta-catenin signaling. Oncotarget, 7, 29371-86.

Li XL, Eishi Y, Bai YQ, et al (2004). Expression of the SRY related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol, 24, 257-63.

Li M, He Y, Dubois W, et al (2012). Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell, 46, 30-42.

Li P, Cao Y, Li Y, et al (2014). Expression of Wnt-5a and B-catenin in primary hepatocellular carcinoma. Int J Clin Exp Pathol, 7, 3190-5.

Liu J, Li W, Deng M, et al (2016). Immunohistochemical determination of p53 protein overexpression for predicting p53 gene mutations in hepatocellular carcinoma: A Meta-Analysis. PLoS One, 11, e0159636.

Lu LC, Shao YY, Lee YH, et al (2014). beta-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma. Oncology, 87, 159–66.

Luis TC, Weerkamp F, Naber BAE, et al (2009). Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood, 113, 546–54.

Mohamed WS, Omar MM, Khayri TM, Fakhir JM (2008). Assessment of the proliferative marker Ki-67 and p53 protein expression in HBV- and HCV-related hepatocellular carcinoma cases in Egypt. Int J Health Sci, 2, 27-34.

O’Brien CA, Pollett A, Gallinger S, Dick J E (2007). A human colon cancer cell capable of initiating tumour growth in immunodeﬁcient mice. Nature, 445, 106–10.

Ozakyl A (2017). Global epidemiology of hepatocellular carcinoma (HCC) epidemiology. J Gastrointest Cancer, 2017.

Petruzziello A (2018). Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma Open Virol J, 12, 26-32.

Pez F, Lopez A, Kim M, et al (2013). Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol, 59, 1107-17.

Phillips TM, McBride WH, Pajonk F (2006). The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst, 98, 1777-85.

Richtig G, Aigelsreiter A, Schwarzenbacher D, et al (2017). SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One, 12, e0187814.

Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al (2007). Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol, 20, 474–81.

Samulin Erdem J, Skaug V, Bakke P, et al (2016). Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. BMC Cancer, 16, 28.

Sanada Y, Yoshida K, Ohara M, et al (2006). Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas, 32, 164–70.

Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P (2014). Histopathology of hepatocellular carcinoma. World J Gastroenterol, 20, 15955–64.

Shindoh J, Vauthay JN (2014). Staging of biliary tract and
primary liver tumors. Surg Oncol Clin N Am, 23, 313–22.
Shiraha H, Yamamoto K, Namba M (2013). Human hepatocyte carcinogenesis (review). Int J Oncol, 42, 1133-8.
Stroescu C, Dragnea A, Ivanov B, et al (2008). Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis, 17, 411-7.
Sun C, Sun L, Li Y, et al (2013). Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol, 30, 503-12
Vilchez V, Turcios L, Marti F, Gedaly R (2016). Targeting Wnt/B-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol, 22, 823–32.
Wang Z, Sheng YY, Gao XM, et al (2015). β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol, 3, 936-40.
Yapali S, Tozun N (2018). Epidemiology and viral risk factors for hepatocellular carcinoma in the Eastern Mediterranean countries. Hepatoma Res, 4, 24.
Yimlamai D, Christodoulou C, Galli GG, et al (2014). Hippo pathway activity influences liver cell fate. Cell, 157, 1324–38.
Yin X, Li Y, Jin J, et al (2013). The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett, 5, 1155-62.
Yu J, Vodyanik MA, Smuga-Otto K, et al (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917–20.
Yuan P, Kadara H, Behrens C, et al (2010). Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One, 5, e9112.
Zhang H, Zhang Z, Gao L, et al (2019). miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. OncoTargets Ther, 12, 2149–57.
Zhao X, Sun B, Sun D, et al (2015). Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression. Oncol Rep, 33, 149-56.
Zhong F, Cheng X, Sun S, Zhou j (2017). Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. Oncol Rep, 37, 3061-7.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.